In short
A groundbreaking clinical trial is underway to assess the safety and effectiveness of TP-102, a new topical treatment for diabetic foot infections. This innovative therapy uses a combination of bacteriophages, which are viruses that target specific bacteria, to combat infections caused by common pathogens in diabetic foot ulcers. The study aims to explore how TP-102 performs compared to standard care, potentially offering a new approach to managing this challenging condition.
At a glance
- Study Type
- Phase 2b Clinical Study
- Treatment
- TP-102 (bacteriophage therapy)
- Administration
- Topical application on wound
- Target Condition
- Diabetic foot ulcers infected by specific bacteria
- Primary Objectives
- Safety, tolerability, clinical improvement, wound healing
- Key Inclusion Criteria
- Adults with diabetes, specific foot infection characteristics
- Treatment Duration
- Up to 31 days
- Primary Endpoints
- Adverse events, infection classification changes, wound size reduction
What is F770/05?
F770/05 is one of the five components in a new medication called TP-102. This medication is currently being studied for its potential to treat diabetic foot infections. F770/05 is classified as a bacteriophage, which is a type of virus that specifically targets and destroys bacteria.
TP-102 Bacteriophage Therapy
TP-102 is a bacteriophage cocktail that contains five different bacteriophages, including F770/05. The other components are F44/10, F125/10, F510/08, and F1245/05. This combination is designed to target specific bacteria that commonly cause infections in diabetic foot ulcers.
Bacteriophage therapy is an innovative approach to treating bacterial infections. Instead of using traditional antibiotics, it uses viruses (bacteriophages) that are harmless to humans but can kill specific bacteria.
Target Conditions
TP-102, which includes F770/05, is being developed to treat diabetic foot ulcers infected by specific bacteria. The target bacteria are:
- Acinetobacter baumannii
- Pseudomonas aeruginosa
- Staphylococcus aureus
These bacteria are common causes of infections in people with diabetic foot ulcers, which can be difficult to treat with conventional antibiotics.
Clinical Trial Details
F770/05, as part of TP-102, is currently being studied in a Phase 2b clinical trial. This trial aims to evaluate the safety and effectiveness of TP-102 when applied topically (on the skin) to treat diabetic foot infections.
The main objectives of this study are:
- To assess the safety and tolerability of TP-102 compared to a placebo, in addition to standard care
- To evaluate the clinical improvement in diabetic foot infection classification
- To examine the effects of TP-102 on wound healing
Eligibility Criteria
To participate in this study, patients must meet certain criteria. Some key eligibility requirements include:
- Being 18 years or older
- Having a diagnosis of Type I or Type II diabetes
- Having a diabetic foot infection that meets specific criteria, such as being present for at least 3 weeks and having a wound area of 20 cm² or less
- Having an infection caused by at least one of the target bacteria (Pseudomonas aeruginosa, Staphylococcus aureus, or Acinetobacter baumannii)
There are also several exclusion criteria, such as pregnancy, breastfeeding, or having certain medical conditions that might interfere with the study.
Treatment Administration
TP-102, which contains F770/05, is administered as a topical suspension. This means it's applied directly to the infected wound on the foot. The treatment is given in addition to standard care for diabetic foot infections.
Expected Outcomes
The researchers are looking at several outcomes to determine if TP-102 (including F770/05) is effective. These include:
- Reduction in wound surface area
- Improvement in infection classification
- Changes in wound healing markers
- Eradication of the target bacteria
They will compare these outcomes between patients receiving TP-102 and those receiving a placebo, both in addition to standard care.
Safety Considerations
As with any new treatment, safety is a primary concern. The study will closely monitor for any side effects or adverse events related to the use of TP-102. Patients with hypersensitivity to any component of the investigational product are not eligible to participate in the study.
It's important to note that while F770/05 and TP-102 show promise, they are still experimental treatments. More research is needed to fully understand their effectiveness and safety in treating diabetic foot infections.